Hone Health
Membership Telehealth TRT Platform (CEO Saad Alam)
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Prescribes FDA-regulated testosterone products via licensed clinicians
Reference only. Not medical advice.
What can go wrong
All testosterone prescribing carries the standard TRT risk profile (polycythemia, fertility suppression, cardiovascular and prostate monitoring needs). Hone's claims about a 90-day retest cadence and hypogonadal-only prescribing are company statements; independent verification of adherence is not established here.
This is something to take to a clinician. The Atlas can tell you what is known about hone health in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Hone Health, reportedly launched around 2020 and led by co-founder and CEO Saad Alam, is a membership-based telehealth platform offering at-home hormone testing and, for men it states are hypogonadal, testosterone therapy. Hone states it retests patients every 90 days and prescribes only to hypogonadal men. The company was named in KFF Health News / CBS News reporting (2024) on TRT telehealth, and KFF reported that Hone is among sites that pitch to military veterans.
Tiered membership; the company says it tests every 90 days.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Hone sells tiered memberships: an entry-level lab-testing tier (stated ~$65), a premium tier including labs plus physician consultation, and a separately billed TRT tier. Men identified by the platform as hypogonadal may be prescribed injections, cream, or dissolvable troches.
Safety in detail
TRT involves significant physiological effects and requires evaluation and ongoing monitoring by a qualified physician. Self-administration without medical oversight carries documented health risks.
What it does to fertility
Exogenous testosterone in any form Hone offers (injection, cream, troche) can suppress spermatogenesis and impair fertility.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Total/free testosterone
- Hematocrit
- PSA (age-appropriate)
- Estradiol
What people get wrong
Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.
Who profits, and who pushes back
Fitness/athlete promoters
Specific Hone athlete/influencer partnerships are not publicly confirmed here. Where a creator is compensated, that relationship is a paid endorsement and must be disclosed under FTC guides; treat any individual paid status as unverified until confirmed.
The people taking it
Per KFF Health News (2024), Hone is among telehealth TRT sites that pitch to military veterans, alongside general middle-aged-male fatigue/low-energy audiences.
At a glance
- Founded
- Reportedly ~2020 (CEO Saad Alam)
- CEO
- Saad Alam (co-founder)
- Entry lab test
- ~$65 (company stated)
- Stated retest cadence
- Every 90 days (company claim)
- Treatment forms
- Injections, cream, dissolvable troches (company stated)
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Hone Health. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.